Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Medulloblastoma 2Rhabdoid Tumor 1Neuroectodermal Tumors, Primitive 1Meningeal Carcinomatosis 1Lung Neoplasms 1Intracranial Germ Cell Tumors 1Infratentorial Neoplasms 1Glioma 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 114Temozolomide 104Bevacizumab 71Radiotherapy 67Magnetic Resonance Spectroscopy 67Carboplatin 29pembrolizumab 28Irinotecan 26Surgical Procedures, Operative 25Radiation 23Nivolumab 23Etoposide 22Magnetic Resonance Imaging 21Ipilimumab 21Erlotinib Hydrochloride 21Cyclophosphamide 21Surveys and Questionnaires 19Aminolevulinic Acid 18Specimen Handling 16Pemetrexed 16Mental Status and Dementia Tests 16Cisplatin 16Carmustine 15Topotecan 14Trastuzumab 13Saline Solution 12Neuropsychological Tests 12Gefitinib 11Filgrastim 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Brain Neoplasms × Craniospinal Irradiation × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡